ClinicalTrials.Veeva

Menu

Efficacy and Safety of Second-Line Helicobacter Pylori Eradication

Seoul National University logo

Seoul National University

Status

Active, not recruiting

Conditions

HELICOBACTER PYLORI INFECTIONS

Treatments

Drug: P-CAB-BM quadruple regimen
Drug: Moxifloxacin triple regimen

Study type

Interventional

Funder types

Other

Identifiers

NCT07855497
B-2011-649-004
2025-ER1104-01 (Other Grant/Funding Number)

Details and patient eligibility

About

Subjects with persistent H. pylori infection after first-line treatment failure receives either a 14-day PPI-based moxifloxacin triple regimen (esomeprazole, amoxicillin, and moxifloxacin) or a 14-day P-CAB-bismuth-containing moxifloxacin quadruple regimen (tegoprazan, amoxicillin, moxifloxacin, and bismuth).

Full description

Participants with confirmed failure of first-line H. pylori eradication therapy are randomly assigned to receive either P-CAB and BM-containing moxifloxacin quadruple therapy (tegoprazan 50 mg twice daily, amoxicillin 500 mg four times daily, moxifloxacin 400 mg once daily, and tripotassium dicitrate BM 300 mg four times daily; P-CAB-BM quad regimen) or conventional PPI-based moxifloxacin triple therapy (esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, and moxifloxacin 400 mg once daily; moxifloxacin triple regimen) for 14 days.

Enrollment

141 patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients with persistent H. pylori infection after failure of first-line eradication therapy
  • H. pylori infection was confirmed by at least one positive result on the 13C-urea breath test (UBT), rapid urease test, or histology
  • Patients who provided written informed consent and who are able to complete symptom questionnaires

Exclusion criteria

  • Individuals younger than 19 years, pregnant or lactating females, patients with previous total gastrectomy, severe systemic diseases, recent use of antibiotics or acid-suppressive medications, drug allergies, or other conditions considered inappropriate by the investigators

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

141 participants in 2 patient groups

P-CAB-BM quad
Experimental group
Description:
14-day PPI-based moxifloxacin triple regimen (esomeprazole, amoxicillin, and moxifloxacin)
Treatment:
Drug: P-CAB-BM quadruple regimen
Moxifloxacin triple
Active Comparator group
Description:
14-day P-CAB-bismuth-containing moxifloxacin quadruple regimen (tegoprazan, amoxicillin, moxifloxacin, and bismuth)
Treatment:
Drug: Moxifloxacin triple regimen

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems